Breaking News, Collaborations & Alliances

Rentschler Biopharma and ATUM Ink Licensing Agreement

Leap-In Transposase technology will be integrated into Rentschler’s in-house process to complement existing CLD offering.

By: Contract Pharma

Contract Pharma Staff

Rentschler Biopharma SE, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and ATUM, a global specialist in synthetic biology solutions, have signed a full CDMO licensing agreement for the Leap-In Transposase platform.   ATUM will provide Rentschler Biopharma full access to its Leap-In Transposase platform. The technology platform is an integrated solution combining proprietary re-coding algorithms, unique genetic vector elements as well as a transposon-...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters